Close



Feb 27, 2024 08:30AM
Nov 5, 2019 04:55AM
Mar 4, 2019 08:01AM
May 11, 2018 05:03AM
Jan 17, 2018 09:22AM
Nov 22, 2017 04:44AM
Jun 22, 2017 04:54PM Halozyme Therapeutics (HALO) Could See $23 Million In Revenue From Rituxan Hycela - Barclays
May 24, 2017 04:05PM
May 19, 2017 05:39AM
May 18, 2017 09:25PM
Feb 23, 2017 04:30PM
Jan 5, 2017 09:24AM
May 10, 2016 09:36AM
May 9, 2016 06:25PM After-Hours Stock Movers 05/09: (STMP) (OPK) (HALO) Higher; (NLNK) (GPS) (BLOX) (RAX) Lower (more...)
Mar 2, 2016 04:30PM
Feb 1, 2016 10:38AM
Sep 22, 2015 07:24AM
Dec 24, 2014 10:18AM
Aug 2, 2013 06:58AM
Aug 16, 2012 05:27PM
Jun 12, 2012 05:44PM Barclays Maintains an 'Overweight' on Halozyme Therapeutics (HALO); Underappreciated Assets Plus Possible Partnership On Deck
Mar 8, 2012 02:49PM
Mar 8, 2012 07:51AM
Feb 10, 2012 08:36AM
Feb 9, 2012 04:18PM
Mar 14, 2011 01:25PM
Oct 12, 2010 01:54PM
Oct 6, 2010 12:55PM UPDATE - Barclays Initiates Coverage on Halozyme Therapeutics (HALO) with an Overweight; Leveraging Next Gen. Biologics Delivery
Oct 6, 2010 09:35AM
Sep 9, 2010 09:14AM

96,869 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All